Corify Care has received clearance from the US Food and Drug Administration for its ACORYS® System, a breakthrough non-invasive cardiac mapping platform designed to provide real-time four-dimensional electroanatomical mapping of the heart.
The system introduces a new approach to electrophysiology by combining high-resolution 3D anatomical models with live electrical activity mapping.
ACORYS® is the first imageless cardiac mapping platform capable of delivering a complete four-chamber view of heart electrical activity in real time.
The technology has been developed to support faster, safer and more precise ablation procedures while improving clinical workflow efficiency.
Unlike conventional systems, ACORYS® does not require CT or MRI imaging before procedures. It also enables clinicians to assess arrhythmia mechanisms without inducing unstable arrhythmias.
The platform supports single-beat global cardiac mapping and rapid identification of arrhythmogenic substrates linked to ventricular tachycardia, atrial tachyarrhythmias and cardiac desynchronisation.
According to the company, the system has been clinically validated in more than 2,500 patients across leading electrophysiology centres in Europe.
Clinical studies demonstrated high accuracy in identifying arrhythmia mechanisms and ablation targets.
Following FDA clearance, Corify Care plans a phased commercial rollout of the ACORYS® platform across the United States.
